Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · TYCHE INDUSTRIES LTD. · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
TYCHE INDUSTRIES LTD.
BSE: 532384
BSE: 532384
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
TYCHE INDUSTRIES LTD.
StateQ4 FY26 filed
Last close · 9 Oct 2026₹104.15
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA15.6 · 0.76 · 8.8
TYCHE INDUSTRIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 62 | 75 | 70 | 65 | 54 |
| EBITDA (ex other income) | 10 | 16 | 13 | 11 | 2 |
| margin % | 16.5 | 21.3 | 18.2 | 17.2 | 4.2 |
| Owners' profit | 9 | 14 | 12 | 12 | 7 |
| EPS, as reported (₹) | 9.17 | 13.74 | 11.78 | 12.19 | 6.70 |
| ROE % · ROCE % | 9.0 · 11.8 | 12.1 · 15.9 | 9.7 · 12.8 | 9.1 · 12.1 | 4.9 · 6.7 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 5 | 7 | 8 | 9 | 3 |
| Capex | (1) | (2) | (3) | 0 | (4) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · TYCHE INDUSTRIES LTD. · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16 | 21 | 18 | 12 | 13 | 14 | 11 | 16 |
| Profit before tax | 4 | 5 | 6 | 1 | 3 | 2 | 2 | 2 |
| Net profit | 3 | 4 | 5 | 1 | 2 | 2 | 2 | 1 |
| EPS (₹) | 2.66 | 3.90 | 4.63 | 1.00 | 2.37 | 1.49 | 1.78 | 1.05 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,22,229 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,48,067 | 84.9 | 14.80 | 64.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,270 | 73.8 | 8.89 | 38.8 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,10,978 | 24.8 | 3.75 | 14.4 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,07,937 | 98.6 | 19.87 | 60.1 | 16.4 | 17.2 | 7.2 | 32.0 |
| CIPLA LTD | 1,05,570 | 31.3 | 3.06 | 16.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| DR. REDDY S LABORATORIES | 98,530 | 30.5 | 2.58 | 13.2 | 10.9 | 13.0 | 12.1 | 15.0 |
| MANKIND PHARMA LIMITED | 98,294 | 48.1 | 5.94 | 27.1 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 15.8 | 31.2 | 34 of 158 | 79% |
| P/B | 0.8 | 3.1 | 12 of 163 | 93% |
| ROCE | 6.7 | 10.8 | 119 of 183 | 35% |
| ROE | 4.9 | 9.8 | 117 of 166 | 30% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| EBITDA margin | 14.1 | 17.5 | 94 of 165 | 43% |
| Revenue growth | 31.0 | 16.3 | 44 of 161 | 73% |
| Profit growth | 12.4 | 30.9 | 100 of 158 | 37% |
| Market cap | 108 | 857 | 131 of 181 | 28% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · TYCHE INDUSTRIES LTD. · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Oct 2026 · Tyche Industries AGM: All resolutions passed, Rs 3.50 dividend declared | board shareholder meetings | low | — | — |
| 30 Sept 2026 · Tyche Industries 28th AGM approves 35 percent dividend of Rs 3.50 per share | board shareholder meetings | low | — | — |
| 26 Sept 2026 · Trading window closes Oct 1 till 48 hrs after Q2 FY26 results | compliance | minimal | — | — |
| 5 Sept 2026 · Corrigendum to FY25-26 Annual Report - Ratio Analysis Notes Corrected | results | low | — | — |
| 3 Sept 2026 · Tyche Industries sends 28th AGM notice and Annual Report weblink to shareholders | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Newspaper publication of 28th AGM notice and e-voting details | compliance | minimal | — | — |
| 3 Sept 2026 · Tyche Industries 28th AGM notice published; meeting on Sep 30, 2026 | compliance | minimal | — | — |
| 2 Sept 2026 · 28th Annual Report FY2025-26 with Rs 3.50 per share dividend | results | medium | — | — |
| 2 Sept 2026 · Tyche Industries fixes record date for FY26 final dividend | corporate actions | medium | — | — |
| 2 Sept 2026 · Book Closure for 28th AGM on September 30, 2026 | corporate actions | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in